Evidence map›Paper›PMID 33920503›Full record

ReviewPharmaceutics2021

Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect.

Alex N Frickenstein, Jordan M Hagood, Collin N Britten, Brandon S Abbott, Molly W McNally, Catherine A Vopat, Eian G Patterson, William M MacCuaig, Ajay Jain, Keisha B Walters and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Porous silicon and silica carriers for delivery of peptide therapeutics.Drug delivery and translational research · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alex N FrickensteinStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA.ORCID 0000-0001-6115-9638
Jordan M HagoodStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA.
Collin N BrittenSchool of Chemical, Biological, and Materials Engineering, University of Oklahoma, Norman, OK 73019, USA.
Brandon S AbbottSchool of Chemical, Biological, and Materials Engineering, University of Oklahoma, Norman, OK 73019, USA.ORCID 0000-0002-1896-2414
Molly W McNallyStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA.
Catherine A VopatStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA.
Eian G PattersonDepartment of Biology, University of Oklahoma, Norman, OK 73019, USA.ORCID 0000-0002-6061-4106
William M MacCuaigStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA.
Ajay JainDepartment of Surgery, University of Oklahoma, Oklahoma City, OK 73104, USA.
Keisha B WaltersSchool of Chemical, Biological, and Materials Engineering, University of Oklahoma, Norman, OK 73019, USA.ORCID 0000-0002-0875-2659
Lacey R McNallyStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA.

Funding

Stroma Targeted Theranostic Nanoparticles for Pancreatic CancerR01CA212350 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MCNALLY, LACEY R · 2017 to 2021
$1.7M
Non-Invasive Detection of Tumor Extracellular pH using Multispectral Optoacoustic TomographyR01CA205941 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MCNALLY, LACEY R · 2016 to 2021
$1.7M
Theranostic Nanoparticles For Detection and Treatment of Pancreatic CancerR01EB020125 · NIBIB · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MCNALLY, LACEY R · 2016 to 2019
$1.7M
NCI NIH HHS R01CA205941NCI NIH HHS R01CA212350NIBIB NIH HHS R01EB020125
6 · The paper itself

Abstract

Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or treat myriad malignant diseases in preclinical models. As MSNs continue transitioning into clinical trials, a thorough understanding of the characteristics of effective MSNs is necessary. This review highlights recent discoveries and advances in MSN understanding and technology. Specific focus is given to cancer theragnostic approaches using MSNs. Characteristics of MSNs such as size, shape, and surface properties are discussed in relation to effective nanomedicine practice and projected clinical efficacy. Additionally, tumor-targeting options used with MSNs are presented with extensive discussion on active-targeting molecules. Methods for decreasing MSN toxicity, improving site-specific delivery, and controlling release of loaded molecules are further explained. Challenges facing the field and translation to clinical environments are presented alongside potential avenues for continuing investigations.

Indexed as

active targetingcancercontrolled releasemesoporous silicananomedicinetheragnosticstheranosticstoxicity

Identifiers

PMID33920503
PMCPMC8072651

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.